Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 11, 2014, Pages 1209-1213

  Gresle, Melissa ^a,b   Liu, Y ^c   Dagley, L F ^d   Haartsen, J ^e   Pearson, F ^e   Purcell, A W ^d,f   Laverick, L ^a   Petzold, A ^g   Lucas, R M ^h   Van Der Walt, A ^b   Prime, H ^e,i   Morris, D R ^a   Taylor, B V ^j   Shaw, G ^k,l   Butzkueven, H ^a,b,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BOX HILL HOSPITAL   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

ⁱ IMED MIA   (Australia)

^j UNIVERSITY OF TASMANIA   (Australia)

^k UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^l EnCor Biotechnology Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN H;

ADULT; BLOOD; BRAIN; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHOSPHORYLATION; SEVERITY OF ILLNESS INDEX;

ADULT; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROFILAMENT PROTEINS; NEUROIMAGING; PHOSPHORYLATION; SEVERITY OF ILLNESS INDEX;

EID: 84896060516     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306789     Document Type: Article

References (17)

1. Stadelmann C, Albert M, Wegner C, et al. Cortical pathology in multiple sclerosis. Curr Opin Neurol 2008;21:229-34.
2. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 2011;93:1-12.
3. Gresle MM, Butzkueven H, Shaw G. Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int 2011; doi:10.1155/2011/315406
4. Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-4.
5. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-98.
6. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322-9.
7. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132-9.
8. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-92.
9. Taylor BV, Lucas RM, Dear K, et al. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult Scler 2010;16:398-405.
10. Lucas RM, Ponsonby A-L, McMichael AJ, et al. Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Mult Scler 2007;13:827-39.
11. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
12. Gresle MM, Shaw G, Jarrott B, et al. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J Neurosci Res 2008;86:3548-55.
13. Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009;111:1182-91.
14. Eikelenboom MI, Uitdehaag BM, Petzold A. Blood and CSF biomarker dynamics in multiple sclerosis: implications for data interpretation. Mult Scler Int 2011; doi:10.1155/2011/315406
15. Kuhlmann T, Lingfield G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12.
16. Fisher E, Ruddick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373-7.
17. van Walderveen MA, Lycklama a Nijeholt GJ, Ader HJ, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 2001;58:76-81.